Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 2308 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Choosing a Gliptin

Gupta Vishal, Kalra Sanjay

Year : 2011| Volume: 15| Issue : 4 | Page no: 298-308

   This article has been cited by
 
1 Teneligliptin inhibits lipopolysaccharide-induced cytotoxicity and inflammation in dental pulp cells
Xin Liu,Yan Cao,Yan Zhang,Baozhen Sun,Haiying Liang
International Immunopharmacology. 2019; 73: 57
[Pubmed]  [Google Scholar] [DOI]
2 The Impact of a Large Bolus Dose of l-leucine and l-isoleucine on Enteroendocrine and Pancreatic Hormones, and Glycemia in Healthy, Inactive Adults
Daniel E. Newmire,Eric Rivas,Sarah E. Deemer,Darryn S. Willoughby,Victor Ben-Ezra
Nutrients. 2019; 11(11): 2650
[Pubmed]  [Google Scholar] [DOI]
3 DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment
Momir Mikov,Nebojša Pavlovic,Bojan Stanimirov,Maja Ðanic,Svetlana Golocorbin-Kon,Karmen Stankov,Hani Al-Salami
European Journal of Drug Metabolism and Pharmacokinetics. 2019;
[Pubmed]  [Google Scholar] [DOI]
4 The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-?B
Suxia Ma,Zhifeng Bai,Huiying Wu,Wei Wang
European Journal of Pharmacology. 2019;
[Pubmed]  [Google Scholar] [DOI]
5 The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells
Feng-li Hao,Xiao-fang Han,Xiao-li Wang,Zhi-ru Zhao,Ai-hong Guo,Xin-jian Lu,Xiong-fei Zhao
Biomedicine & Pharmacotherapy. 2019; 109: 181
[Pubmed]  [Google Scholar] [DOI]
6 Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury
Zhen Zhang,Xiang Jin,Chunfeng Yang,Yumei Li
Biomedicine & Pharmacotherapy. 2019; 109: 468
[Pubmed]  [Google Scholar] [DOI]
7 Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture
Heng Li,Junjun Zhang,Li Lin,Lishuai Xu
International Immunopharmacology. 2019; 66: 162
[Pubmed]  [Google Scholar] [DOI]
8 Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: R etrospective data for 10?256 individuals from the U nited K ingdom and G ermany
Kamlesh Khunti,Thomas R. Godec,Jesús Medina,Laura Garcia-Alvarez,Josh Hiller,Marilia B. Gomes,Javier Cid-Ruzafa,Bernard Charbonnel,Peter Fenici,Niklas Hammar,Kiyoshi Hashigami,Mikhail Kosiborod,Antonio Nicolucci,Marina V. Shestakova,Linong Ji,Stuart Pocock
Diabetes, Obesity and Metabolism. 2018; 20(2): 389
[Pubmed]  [Google Scholar] [DOI]
9 Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor
Lina Rozano,Muhammad Redha Abdullah Zawawi,Muhamad Aizuddin Ahmad,Indu Bala Jaganath
Advances in Bioinformatics. 2017; 2017: 1
[Pubmed]  [Google Scholar] [DOI]
10 Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus
Maurílio de Souza Cazarim,Estael Luzia Coelho da Cruz-Cazarim,André de Oliveira Baldoni,Thais Bueno Enes dos Santos,Paula Gonçalves de Souza,Ingrid de Almeida Silva,Roberta Niriam Reis Rodrigues,Alda Cristina Franco Correa Maia,Leonardo Régis Leira Pereira,Cristina Sanches
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;
[Pubmed]  [Google Scholar] [DOI]
11 Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
Khosro Keshavarz,Farhad Lotfi,Ehsan Sanati,Mahmood Salesi,Amir Hashemi-Meshkini,Mojtaba Jafari,Mohammad M. Mojahedian,Behzad Najafi,Shekoufeh Nikfar
DARU Journal of Pharmaceutical Sciences. 2017; 25(1)
[Pubmed]  [Google Scholar] [DOI]
12 Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
Cristina Mega,Edite Teixeira-de-Lemos,Rosa Fernandes,Flávio Reis
Journal of Diabetes Research. 2017; 2017: 1
[Pubmed]  [Google Scholar] [DOI]
13 The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy
Liberata Sportiello,Concetta Rafaniello,Cristina Scavone,Cristiana Vitale,Francesco Rossi,Annalisa Capuano
International Journal of Cardiology. 2016; 202: 731
[Pubmed]  [Google Scholar] [DOI]
14 Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013–2016) analysis
Christian Leporini,Rosanna Piro,Francesco Ursini,Francesca Maida,Caterina Palleria,Franco Arturi,Maria Pavia,Giovambattista De Sarro,Emilio Russo
Expert Opinion on Drug Safety. 2016; 15(sup2): 17
[Pubmed]  [Google Scholar] [DOI]
15 Comparison of charges and resource use associated with saxagliptin and sitagliptin
Varun Vaidya,Keyuri Adhikari,Jack Sheehan,Iftekhar Kalsekar
Health Economics Review. 2015; 6(1)
[Pubmed]  [Google Scholar] [DOI]
16 Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
Sandeep Chakraborty,Adela Rendón-Ramírez,Bjarni Ásgeirsson,Mouparna Dutta,Anindya S. Ghosh,Masataka Oda,Ravindra Venkatramani,Basuthkar J. Rao,Abhaya M. Dandekar,Félix M. Goñi
F1000Research. 2015; 2: 286
[Pubmed]  [Google Scholar] [DOI]
17 The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
Sandeep Chakraborty,Adela Rendón-Ramírez,Bjarni Ásgeirsson,Mouparna Dutta,Anindya S. Ghosh,Masataka Oda,Ravindra Venkatramani,Basuthkar J. Rao,Abhaya M. Dandekar,Félix M. Goñi
F1000Research. 2015; 2: 286
[Pubmed]  [Google Scholar] [DOI]
18 DPP-4 inhibitors: pharmacological differences and their clinical implications
Antonio Ceriello,Liberata Sportiello,Concetta Rafaniello,Francesco Rossi
Expert Opinion on Drug Safety. 2014; 13(S1): 57
[Pubmed]  [Google Scholar] [DOI]
19 Alogliptin for the treatment of Type 2 diabetes
Yutaka Seino,Daisuke Yabe
Expert Review of Endocrinology & Metabolism. 2014; : 1
[Pubmed]  [Google Scholar] [DOI]
20 Development of a gas chromatography–mass spectrometry method for the analysis of sitagliptin in human urine
Ebru Uçaktürk
Journal of Pharmaceutical and Biomedical Analysis. 2013; 74: 71
[Pubmed]  [Google Scholar] [DOI]
21 Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
Erika Paniago Guedes,Alexandre Hohl,Thais Gomes de Melo,Felipe Lauand
Diabetology & Metabolic Syndrome. 2013; 5(1)
[Pubmed]  [Google Scholar] [DOI]
22 Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
Sandeep Chakraborty,Adela Rendón-Ramírez,Bjarni Ásgeirsson,Mouparna Dutta,Anindya S. Ghosh,Masataka Oda,Ravindra Venkatramani,Basuthkar J. Rao,Abhaya M. Dandekar,Félix M. Goñi
F1000Research. 2013; 2: 286
[Pubmed]  [Google Scholar] [DOI]

 

Read this article